Clinical Trial Update: Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and food interaction of BIA 3-202 in Parkinson's disease; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED